The Pharmacy Times® Epilepsy Resource Center is a comprehensive resource for clinical news and expert insights on treatments for epilepsy.
May 8th 2023
Comorbidities and cognitive impairment worsen non-adherence to anti-seizure medications in older adults.
Treatment Advancements and Management Strategies in Bipolar Disorder to Mitigate Challenges to Patient Care
1.0 Credit / Neurology, Psychiatry
View More
Risks and Liabilities in Pharmacy Practice
1.0 Credit / Law
View More
A Managed Care Focus on Assessing the Armamentarium for Multiple Sclerosis to Better Individualize Treatment
1.5 Credits / Neurology
View More
The Value of Early Intervention With Long-Acting Injectable Antipsychotics to Improve Adherence and Treatment of Schizophrenia
1.5 Credits / Neurology, Psychiatry
View More
The Promising Role of Novel and Emerging Therapies for Amyotrophic Lateral Sclerosis: Clinical and Managed Care Insights
1.0 Credit / Neurology
View More
Understanding the Role of IVIg and SCIg for the Management of CIDP: Information the Pharmacist Needs to Know to Optimize Care, featuring a Patient Perspective
1.5 Credits / Immunology, Neurology
View More
Rare and Treatment-Resistant Epilepsy Syndromes: Identifying and Addressing the Unmet Needs of Patients and Recognizing Opportunities for Pharmacist Intervention
1.5 Credits / Neurology
View More
Strategies for the Management and Treatment of ALS: The Value of Early Diagnosis and Clinical Intervention
3.0 Credits / Neurology
View More
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Leveraging Managed Care to Optimize Best Practices in the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
1.0 Credit / Neurology
View More
Improving Outcomes and Quality of Care in Spinal Muscular Atrophy: Updates in Treatment Advances
2.0 Credits / Neurology
View More
Navigating the Use of Targeted Therapies and Individualizing Care for Patients With Ulcerative Colitis
1.5 Credits / Gastroenterology
View More
New and Emerging Treatment Strategies for Myasthenia Gravis: The Role of the Specialty Pharmacist
1.0 Credit / Neurology
View More
Improving Treatment Access for Spinal Muscular Atrophy: How Managed Care Strategies Can Ease Clinical and Caregiver Burden
1.5 Credits / Neurology
View More
Assessing the Treatment Landscape for Multiple Sclerosis to Better Individualize Care
1.5 Credits / Neurology
View More
Advances in Pharmacotherapy for Excessive Daytime Sleepiness Due to Narcolepsy
2.0 Credits / Neurology
View More
The Role of Long-Term Care and Consultant Pharmacists in the Management of Tardive Dyskinesia
1.0 Credit / Neurology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Abortion Ban Could Be Life-Threatening for Women With Neurological Conditions
July 28th 2022Researchers highlight how a lack of access to medications used to treat multiple sclerosis, migraines, and epilepsy, but not proven safe for pregnancy, threatens child-bearing aged women who live with these conditions.
Read More
FDA Grants Conditional Approval for Drug to Control Seizures in Dogs with Idiopathic Epilepsy
January 19th 2021This conditional approval is the first under the 2018 reauthorization of the FDA’s Animal Drug User Fee Act program, through which Congress granted the FDA a limited expansion of the conditional approval pathway for certain new animal drugs.
Read More
FDA Approves Fenfluramine for Treatment of Seizures Associated with Dravet Syndrome
June 26th 2020Dravet syndrome is a life-threatening, rare, and chronic form of epilepsy and is often characterized by severe, unrelenting seizures despite medical treatment, according to the FDA press release.
Read More
The Evolving Epilepsy Treatment Spectrum: A Review of Antiepileptic Drugs in Late Development
October 29th 2019Given the relatively static rate of seizure freedom with the current antiepileptic drug (AED) armamentarium, a need remains for the development of new compounds to help enable more patients achieve seizure freedom. Fortunately, several investigational therapeutic agents and delivery systems are in phase 3 development, which are being investigated for the treatment of orphan diseases and focal-onset and generalized-onset seizures.
Read More